RecruitingNot ApplicableNCT07218315
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
Sponsor
M.D. Anderson Cancer Center
Enrollment
15 participants
Start Date
Feb 11, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a medical device called CellFX nsPFA Percutaneous Electrode System for people with thyroid carcinoma. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICECellFX nsPFA Percutaneous Electrode System
Patients will undergo thyroid ablation with the CellFX nsPFA system, an outpatient procedure under local anesthesia, or intravenous sedation.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07218315
Related Trials
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT0578692427 locations
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
NCT036473581 location
CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma
NCT061467641 location
Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy
NCT074735182 locations
Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
NCT073595862 locations